IDEXX Laboratories: Worth The Premium

08:00am, Saturday, 08'th Aug 2026
IDEXX Laboratories remains a buy, supported by a durable moat, strong recurring revenue, and a long-term international growth runway. Recent Q2 2026 results showed 9% organic revenue growth, EPS guida
Aurora Investment Managers LLC. bought a new stake in IDEXX Laboratories, Inc. (NASDAQ: IDXX) in the undefined quarter, according to the company in its most recent filing with the Securities and Excha
Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.
Empowered Funds LLC cut its position in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 65.7% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchan

IDEXX Laboratories Q2 Earnings Call Highlights

03:09am, Thursday, 06'th Aug 2026
IDEXX Laboratories (NASDAQ: IDXX) reported second-quarter 2026 revenue growth of approximately 10% on a reported basis and 9% organically, driven by companion animal diagnostics, water and livestock,
Revenue: Increased approximately 10% as reported and 9% organically.CAG Diagnostics Recurring Revenue: Grew 10.3% organically, with double-digit gains in both t
IDEXX Laboratories beats Q2 estimates, expands margins and raises its 2026 EPS outlook as diagnostics demand and adoption fuel growth.
IDEXX Laboratories, Inc. (IDXX) Q2 2026 Earnings Call Transcript

IDEXX Laboratories Q2 Earnings Call Highlights

12:05pm, Tuesday, 04'th Aug 2026
IDEXX Laboratories NASDAQ: IDXX reported second-quarter 2026 revenue growth of approximately 10% on a reported basis and 9% organically, driven by companion animal diagnostics, water and livestock, po
IDEXX Laboratories, Inc. (NASDAQ:IDXX) stock rose Tuesday after the veterinary diagnostics company reported second-quarter results that topped Wall Street estimates and raised its full-year earnings o
The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates a
Idexx Laboratories (IDXX) came out with quarterly earnings of $4.27 per share, beating the Zacks Consensus Estimate of $3.95 per share. This compares to earnings of $3.63 per share a year ago.
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced second quarter results. Second Quarter Results The Company rep
Evaluate the expected performance of Idexx (IDXX) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for b
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX releases 2025 Corporate Responsibility Report highlighting progress against its goals and commitments.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE